<?xml version="1.0" encoding="UTF-8"?>
<p>Histone lysine specific demethylase 1 (LSD1) has been an epigenetic target for cancer therapy since its identification in 2004
 <xref rid="CIT0001" ref-type="bibr">
  <sup>1</sup>
 </xref>. Aberrant over-expression of LSD1 is observed in various leukaemia cell lines and is closely associated with proliferation, migration and invasion
 <xref rid="CIT0002" ref-type="bibr">
  <sup>2â€“4</sup>
 </xref>. These findings underscore the biological importance of LSD1 and therapeutic potential of LSD1 inhibitors for leukaemia therapy
 <xref rid="CIT0005" ref-type="bibr">
  <sup>5</sup>
 </xref>. LSD1 inhibitors (
 <bold>Iadademstat</bold>, 
 <bold>GSK2879552</bold> and 
 <bold>CC-90011</bold>) have entered the clinical stages and are used to treat leukaemia (
 <xref ref-type="fig" rid="F0001">Figure 1</xref>)
 <xref rid="CIT0006" ref-type="bibr">
  <sup>6</sup>
 </xref>. 
 <bold>Dithiocarbamate 26</bold> and 
 <bold>(Bis)urea 31</bold> as potent LSD1 inhibitors also effectively reduce the tumour growth against different human cancer cells
 <xref rid="CIT0007" ref-type="bibr">
  <sup>7</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0008" ref-type="bibr">
  <sup>8</sup>
 </xref>.
</p>
